About Novo Growth Equity

Active, rather than activist shareholder

For Novo Growth Equity, being an investor involves being a long-term partner. We take a dedicated and pragmatic approach towards investing. We are committed to real value creation and are positioned to provide ongoing support until tangible results materialize. We are active, responsible and forward looking shareholders seeking to provide constructive advice and access by utilizing our network, insight and capabilities.

Acting as 'venture catalysts'. Less Private – more Equity

By investing at a later stage in the life cycle of promising life science companies, we can base our investment choices on real data. We see vast potential in the promise of life science technologies, but realise that prudent execution is critical for companies to reach their full potential in a time- and cost-effective way. We aspire to catalyse value creation in our portfolio companies. We are open about what we do and why we do it, and emphasize advancing companies rather than focusing on financial engineering and fluctuating market sentiment.

Typical deal characteristics

• Our typical average investment in each portfolio company is expected to be USD 20-50 million, with the ability to go substantially higher when required.
• Our preferred ownership stake is 15-49% of a company and we will consider investments in both privately held and publicly listed entities.
• We can invest broadly within the global life science area, but will be biased towards late-clinical and early commercial stage product-focused companies.
• Based in Copenhagen, the team has strong ties to key industry stakeholders in both Europe and North America.

Click here to download Novo Growth Equity's brochure